Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 7 to 12

Treating pediatric PTSD with memory reactivation and propranolol

Official title: Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol: A Randomized Placebo-controlled Trial. PPP

Run by University Hospital, Toulouse · NCT04985344 · Data updated 2026-11-12

This study is testing if giving children with PTSD a medication called propranolol along with special memory exercises can help lessen the emotional pain from their traumatic memories.

Quick facts

PhasePhase 3
Study typeInterventional
Ages7 Years to 12 Years
SexAll
Enrollment92 (estimated)
SponsorUniversity Hospital, Toulouse
Academic / other
Locations1 site (Toulouse)
StatusRecruiting
StartedFebruary 1, 2023
Main results expectedSeptember 2027
Study endsSeptember 2027
Registry record updatedAugust 28, 2023
Trial IDNCT04985344 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are children aged 7-12 years who have been diagnosed with PTSD for at least six months.

Probably not a fit

Patients younger than 7 or older than 12 years, or those with contraindications to propranolol, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of propranolol, a beta-blocker, in conjunction with memory reactivation techniques to treat pediatric post-traumatic stress disorder (PTSD) in children aged 7-12. The study aims to disrupt the reconsolidation of traumatic memories, potentially reducing the emotional impact of these memories. Participants will receive either propranolol or a placebo while undergoing memory reactivation sessions. The trial seeks to provide a novel approach to treating PTSD in children, where traditional therapies may lead to high dropout rates due to the intensity of re-experiencing trauma.

Why it matters

Potential benefit: If successful, this approach could offer a new, effective treatment option for children suffering from PTSD.

How similar studies have gone: While traditional trauma-focused therapies have shown some success, the use of propranolol in this context is a novel approach that has not been extensively tested in pediatric populations.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Children aged 7-12 years
* CPTS-RI total score ≥40
* Primary diagnosis of PTSD (6 months or more after the traumatic event)
* Heart rate ≥ 55 bpm
* Systolic blood pressure ≥ 95 mm Hg
* Affiliation to a social security scheme
* Written consent signed by the parents/holders of parental authority and the investigator
* Acceptance of the protocol by the child-Child and Parents/Holders of parental authority fluent in French

Exclusion Criteria:

* Age\<7 years or ≥13 years
* Children whose parents have been deprived of their authority
* Contraindication to propranolol (cardiogenic shock, sinus bradycardia, hypotension (\< fifth percentile oscillometric or \<2SD) (Banker et al., 2016 - see APPENDIX 1), greater than first-degree heart block, heart failure, bronchial asthma and hypersensitivity to propranolol hydrochloride)
* Concurrent medication with possible interactions with propranolol (cf 8.2)
* Concurrent psychotropic drugs that have been shown to be effective in improving symptoms of PTSD (Antidepressants, atypical antipsychotics, mood stabilizers)
* Concurrent psychotherapy (\>1 structured session/month declared by the clinician who follows the child)
* Current active psychosis, anorexia nervosa, bulimia nervosa, binge-eating disorder, attention-deficit hyperactivity disorder, autism spectrum disorder
* Children with psoriasis
* Children with a predisposition to hypoglycemia
* Obsessive-compulsive disorders
* Bipolar Disorders
* Mental retardation,
* Traumatic brain injury (loss of consciousness \> 10 minutes)
* Currently treated with a bradycardic drug
* Concurrent participation to another interventional study
* Renal or Hepatic Impairment
* Pregnancy

Where it's running

  • Toulouse University Hospital
    Toulouse, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.